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TARGETED NANOPARTICLE DELIVERY FOR IN UTERO TREATMENT OF CONGENITAL
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Gregory Tietjen, W Mark Saltzman, Marie Egan, David H Stitelman
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New Haven, CT
Congenital disorders represent a large unmet clinical need with significant morbidity and
premature mortality resulting from mutations and anomalies that can be diagnosed, and
eventually treated, in utero. Nanoparticles (NP) have been used as versatile protective
vessels for the delivery of a variety of therapeutic agents. Importantly, the potency of NPs
can be amplified by modifications to the molecular composition as well as to the delivery to
allow targeting to specific tissues. We hypothesize that optimization of NP targeting both by
nanoparticle modification and the route of administration can increase overall uptake in
specific cells and tissues of interest. To this end, we sought to 1) determine the fetal
biodistribution of NPs based on gestational timing and route of administration; 2) optimize
antibody target selection on tissues of interest; and 3) demonstrate conjugation-dependent
uptake of targeting NPs in target cells. Fluorescent-dye loaded NPs were injected intraamniotically (IA) or intravenously (IV) in mouse fetuses at 15-18 days gestation.
Accumulation of NPs in fetal organs was determined by imaging and microscopy. Antibody
target selection was performed by immunohistochemistry to assess accessibility as well as
antibody binding curves to assess receptor density and binding affinity. Selected antibodies
were conjugated onto fluorescent NPs. Epithelial cells were treated with these targeting NPs
and selective uptake was determined over time by flow cytometry. Fetal mice start
breathing and swallowing amniotic fluid at E16 gestation, allowing for delivery of IA
injected NPs into the lungs and gut. IV injections at E15 and E16 result in greatest
accumulation in fetal liver. Characterization of epithelial cell surface markers was able to
predict targeting results. Conjugation of anti-mucin1 (MUC1) and anti-intracellular
adhesion molecule (ICAM) antibodies resulted in conjugation-dependent increased uptake
in epithelial cells. Targeting of NPs to tissues can be directed by timing and route of
injection. Internalization of NPs can be significantly enhanced by conjugation to antibodies
specific to target cells and tissues. Application of targeting technology in the scope of fetal
therapy is novel and will contribute significantly towards advanced treatments and cures
for congenital disorders.
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INTRODUCTION

There are 8 million children born annually with a genetic disorder or birth defect,
accounting for 6% of total births worldwide (1-4). Of these congenital disorders,
there are over 6,000 known monogenic diseases caused by a single-gene mutation,
occurring with a frequency of 1-2 in every 100 births (5, 6). Some of the most
common genetic pediatric disorders, such as cystic fibrosis, sickle cell anemia, and
β- thalassemia, are caused by single mutations and these diseases carry significant
lifelong morbidity and mortality for afflicted patients (6).

Cystic fibrosis (CF)

exemplifies the unmet burden of congenital disorders in that it is the second most
common lethal inherited disorder of childhood, is rigorously characterized, and yet
no cure has been discovered for the most common variant, a three base-pair
deletion in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
(7, 8). While the development of increasingly sophisticated supportive treatments
is ongoing, no definitive cures exist for genetic diseases.

As treatment modalities for congenital disorders have advanced, so has the
detection of these diseases. Fetal diagnoses of genetic disorders can be made by
well-established methods of amniocentesis, chorionic villous sampling, or
preimplantation genetic diagnosis (9-11). More recently, non-invasive testing of
maternal blood for fragments of fetal DNA has been validated. This method provides
not only a safer alternative but also an earlier diagnosis, as this testing can be
performed as early as seven weeks gestation (9, 12, 13).
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The possibility of earlier fetal diagnosis opens the door for earlier intervention.
Since the 1980’s, the umbilical vessels of the fetus have been safely cannulated
under ultrasound guidance as early as 12 weeks gestation for procedures such as
blood transfusions and drug delivery. In trained hands, the risk of fetal loss is less
than 1% in these procedures (14). Similarly, amniocentesis has been a safe and
approved procedure since the 1970’s with an equally low risk of fetal mortality (11).
Both of these procedures provide routes of access to the developing fetus for
delivery of therapeutic interventions.

Unfortunately, while in utero gene therapy has been suggested as a clinically feasible
approach to cure genetic diseases (15), there exist several barriers to successful
execution of curative correction strategies such as gene editing. One such obstacle
is cell targeting. Ex vivo methods of gene editing to access desired hematopoietic cell
types have shown partial success; however, these methods are cumbersome and
limited to hematologic diseases (16). In vivo methods have been attempted in which
naked DNA of the correct genotype is injected into the patient’s blood stream in the
hope that the correct cells or tissues are targeted. Unsurprisingly, this practice
proved to be neither practical nor efficient (17). In order to successfully deliver any
therapeutic agents to desired cell or tissue types in vivo, they must be stably
packaged.
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To address this obstacle, there has been a rapid growth of research in the area of
nanoscience for medical applications, including the delivery of drugs and other
therapeutic agents via nanoparticles (18-22). Nanoparticles have been used as
stable and modifiable vessels to safely deliver drugs and small molecules, thereby
increasing the circulation time and decreasing the overall dosage required (18, 20).
Several polymers have been approved by the FDA for use in medical devices and
drug delivery systems, such as poly(lactic acid) (PLA) and poly(lactic-co-glycolic
acid) (PLGA). The advantages of these polymers include their biocompatibility,
biodegradability, and ability to regulate the rate of degradation and therefore the
controlled release of contents over time (23-25).

Of particular interest is the ability to load polymer-based nanoparticles with a wide
variety of therapeutic molecules. Nanoparticles have been loaded with hydrophobic
drugs (26, 27), water-soluble drugs (28), various nucleic acids (28-32), siRNA
molecules (28, 29, 31, 32), proteins (26), and plasmid DNA (33). Additionally, gene
editing via nanoparticles has been successfully demonstrated. In published work by
our colleagues, PLGA nanoparticles loaded with a non-nuclease based editing
construct have been shown to efficiently and safely mediate gene correction in
human cells in vitro, cells treated ex vivo, and in animal models in vivo (34-38). Gene
editing carries advantages over gene replacement therapies, which are typically
delivered by viral vectors. Gene editing leaves gene products under native
regulation, is not limited to the cassette size of viral vectors, and does not carry the
risk of tumor formation from non-specific insertion of gene products (17, 39).
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Because the editing construct repairs the mutation in situ, the correction is passed
down to all progeny of the corrected cell (35, 36). This permanent, and indeed
exponential, effect is especially appealing in context of fetal gene editing where stem
cells that create and maintain developing tissues can be accessed. When faced with
the wide range and scope of congenital disorders, nanoparticles offer endless
flexibility as a vessel to deliver a diverse range of therapeutic interventions.

There are several elements to successful nanoparticle targeting that must be
considered, though are often not simultaneously addressed (40). These variables
include both the route and timing of nanoparticle administration, as well as the
molecular characteristics of the nanoparticles (41, 42). In our fetal model, two
routes of administration exist: intravenously through the intravitelline vein and
intra-amniotically. The biodistribution of nanoparticles is likely dependent on the
route of injection. Therefore, knowing in which organs the particles accumulate can
optimize efficacy of therapy. For example, as the liver participates in first-pass
filtration of the blood returning to the fetus through the vitelline vein, it is likely that
intravenous injections will result in a greater accumulation of nanoparticles in this
organ and hepatic or hematopoietic disorders could be more easily targeted.
Furthermore, knowledge of the developmental stage of the fetus can be harnessed
to optimize the temporal targeting of nanoparticles. It is known that fetuses begin to
breathe and swallow amniotic fluid during gestation to aid in development of the
pulmonary and gastrointestinal systems (43, 44). If intra-amniotic injections are
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performed after these physiologic actions commence, nanoparticles could more
easily be targeted to the lungs and gut.

Nanoparticles are also particularly advantageous due to the flexibility of molecular
characteristics that can widely alter the particle properties. The nanoparticles that
have been used by our group are known to be internalized by many different cell
types. The uptake of nanoparticles into cells is predominantly mediated by
endocytic mechanisms, with subsequent escape of the internalized particles from
the endosomes (24, 45). The kinetics of nanoparticle uptake are dependent on
multiple different characteristics of the particles that can be altered, such as size,
shape, and surface properties (24, 46, 47). Surface properties of nanoparticles have
been modified with the addition of proteins (33, 48-50), cell-penetrating peptides
(23, 29, 51), receptor ligands (31), and cell-specific antibodies (52, 53). Considering
that particle uptake is mediated by endocytosis, which requires contact of the
nanoparticle with the surface of the cell, it is reasonable to suggest that surface
modifications that increase the contact time could subsequently increase the rate of
internalization.

Conjugation of specific antibodies to nanoparticles increases particle functionality
by prolonging cell surface binding, as well as actively targeting specific cell types
(53-55). Currently, a large focus of targeted nanoparticles has been in the field of
cancer therapeutics, where much of the development of active targeting has been
realized (56, 57). Our work proposes an alternative and novel use for targeting
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nanoparticles. Prior studies from our group have shown that gene editing
nanoparticles delivered intranasally to adult mice with cystic fibrosis achieve 1%
editing in lung tissue (58). While not phenotypically relevant, these results indicate
that gene editing is possible and present a foundation upon which we hope to
improve. In this study, antibody-conjugated nanoparticles were used to achieve cellspecific targeting and increase particle uptake. By adding polyethylene glycol (PEG),
another FDA-approved polymer, to PLA or PLGA as block copolymers, the functional
groups can be harnessed for antibody conjugation by carboxyl amine crosslinking
(53). The use of antibody-conjugated nanoparticles has been shown to improve
uptake efficiency in cells and tissues (53) and this technology has been approved for
use in clinical trials (59, 60). Importantly, the presence of antibody targeting ligands
does not alter the biodistribution of nanoparticles in vivo (41, 61-64). These
polymer nanoparticles, therefore, present a safe, biocompatible, and targetable
method of delivering therapeutics to cells and tissues.

The therapeutic potential of loaded nanoparticle delivery could be further
maximized by treating early during development. In utero delivery of treatments,
including gene editing reagents, could mitigate the burden of congenital disorders
that afflict millions of patients around the world. As a clinical patient, the fetus offers
several potential therapeutic advantages over the post-natal host (65). The
developing fetus is composed of a proportionally greater number of stem and
progenitor cells, which can exponentially increase the potency of gene editing
strategies. Additionally, stem cells of the brain, skin, muscle, liver, and blood are
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more susceptible to editing during development due to their massive proliferation
and migration (66-70). Furthermore, in utero intervention takes advantage of the
fetus’ immature (and therefore immunotolerant) immune system as well as the
fetus’ small relative size. To give the same dose-per-weight of nanoparticles in a
larger organism would require unrealistic treatment volumes and quantity of
reagents. Above all, there is a clinical advantage to preventing a disease phenotype
before it manifests.

In utero delivery of targeting nanoparticles has the potential to optimize the efficacy
of therapeutic intervention, both by increasing cellular uptake and by intervening at
a developmentally advantageous time point. Therefore, the central hypothesis of
this thesis is that optimization of nanoparticle delivery and targeting by
considering both nanoparticle modification and the route of administration
can increase the overall uptake of particles in specific cells and tissues of
interest. The application of targeting nanoparticle technology can improve upon the
current therapies in adult tissues, while implementing this technology in a novel
fetal space provides the opportunity for earlier and clinically significant disease
intervention. To test the validity of this hypothesis, we have generated these specific
aims:
Specific Aim 1: To determine the fetal biodistribution of nanoparticles based on
gestational timing of injection as well as route of injection (intra-amniotic vs
intravenous).
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Specific Aim 2: To optimize antibody target selection on specific cells and tissues
of interest in both adult and fetal models.
Specific Aim 3: To determine conjugation-dependent uptake of targeting
nanoparticles.
This is innovative because targeting technology has not been applied in the scope of
fetal therapy and we expect the outcomes of this work to contribute to the
development of more advanced treatments and cures for congenital disorders.
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MATERIALS AND METHODS

Nanoparticle Synthesis and Characterization
PLGA Nanoparticles
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) were made with 50:50
ester-terminated, 5-10kDa MW PLGA polymer obtained from LACTEL Absorbable
Polymers. Fluorescent dyes used were Coumarin 6 (C6) (Ex = 460 nm, Em = 500
nm) obtained from Sigma, used at final wt dye/wt polymer ratio of 2%, or 3,3′dioctadecyloxacarbocyanine perchlorate (DiO) (Ex = 484 nm, Em = 501 nm)
obtained from Thermo Scientific, used at 0.5% w/w. Fluorescent dye-encapsulated
PLGA nanoparticles were formulated by two methods.

PLGA NPs were formulated by single-emulsion solvent evaporation technique (35).
Dyes were dissolved in dimethyl sulfoxide (DMSO), added to PLGA dissolved in
dichloromethane (DCM), and diluted to the correct concentration. The polymer-dye
mixture was added dropwise under vortex to 5% polyvinyl alcohol (PVA) in water
and sonicated. This emulsion was poured into 0.3% PVA in water and stirred at
room temperature for 3 hours. NPs were collected by centrifugation and
reuspended in water. One aliquot was removed for dynamic light scattering (DLS).
NPs were then frozen at -80°C and lyophilized for 48 hours in preweighed
Eppendorf tubes. Final weight of dehydrated NPs was noted and NPs were stored at
-20°C.
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PLGA NPs were also formulated using the NanoAssemblr Benchtop system by
Precision Nanosystems. Dyes were dissolved in DMSO, added to PLGA dissolved in
10% DMSO in acetonitrile, and diluted to the correct concentration. The polymerdye mixture was injected through the organic inflow channel of the microfluidic
mixer and a 2% PVA in water solution was injected through the aqueous inflow
channel of the microfluidic mixer. The NPs were created with a 1:1 flow rate of
aqueous to organic solvents, 8 ml/min total flow rate, and 2 ml total volume. NPs
were collected in water. One aliquot was removed for DLS. Solvent was removed by
centrifugation and washing. NPs were then frozen at -80°C and lyophilized for 48
hours in preweighed Eppendorf tubes. Final weight of dehydrated NPs was noted
and NPs were stored at -20°C.

Standard curves for size distribution of PLGA NPs were previously created by
members of the Saltzman lab. NPs were fabricated with 20 mg/ml PLGA to obtain a
size of 150nm.

PLA- PEG Nanoparticles
Polylactic acid – polyethylene glycol (PLA-PEG) polymer was 16-5 kDal MW and
obtained from PolySciTech. DiO fluorescent dye at 0.5% w/w was encapsulated in
the NPs. Fluorescent PLGA nanoparticles were formulated by two methods.

PLA-PEG NPs were prepared by nanoprecipitation procedure (71). PLA-PEG
polymer was dissolved in DMSO and diluted to the correct concentration. DiO was
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dissolved in DMSO and added to dissolved polymer solution. Polymer-dye solution
was added dropwise under vortex to deionized water. NPs were then filtered
through 1.2 μm cellulose acetate membrane to remove free dye or polymer
aggregates. One aliquot was removed for DLS. NPs were left stirring overnight to
evaporate solvent. One aliquot was lyophilized for 48 hours in a preweighed
Eppendorf tube to determine final concentration. Remainder of aliquots were snap
frozen in liquid nitrogen and stored at -80°C.

PLA-PEG NPs were also formulated using the NanoAssemblr Benchtop system by
Precision Nanosystems. Dyes were dissolved in DMSO, added to PLGA dissolved in
75% DMSO in acetonitrile, and diluted to the correct concentration. The polymerdye mixture was injected through the organic inflow channel of the microfluidic
mixer and water was injected through the aqueous inflow channel of the
microfluidic mixer. The NPs were created with a 1:1 flow rate of aqueous to organic
solvents, 2 ml/min total flow rate, and 2 ml total volume. NPs were collected in
water. One aliquot was removed for DLS. Solvent was removed by tangential flow
filtration using the KR2i TFF System from Spectrum Labs. NP batches were
concentrated by a factor of 10 to a final volume of 5ml and dialyzed 10 times. One
aliquot of dialyzed and concentrated NPs was lyophilized for 48 hours in a
preweighed Eppendorf tube to determine final concentration. Remainder of aliquots
were snap frozen in liquid nitrogen and stored at -80°C.
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PLA-PEG concentrations ranging from 5 mg/ml to 50 mg/ml were used to fabricate
NPs using the NanoAssemblr Benchtop system. NP size was determined by DLS and
a standard curve was produced. PLA-PEG NPs were fabricated with 30 mg/ml PLAPEG to obtain a size of 150nm.

Characterization by Dynamic Light Scattering
Dynamic Light Scattering (DLS) was performed to measure NP diameter and
distribution. Size distribution was measured by polydispersion index (PDI). DLS was
performed using a Malvern Nano-ZS by Malvern Instruments.

Characterization by Scanning Electron Microscopy
An aliquot from each NP batch was analyzed using scanning electron microscopy
(SEM). NPs were applied to SEM stubs and sputter coated with 25-nm thick layer of
gold. Images were analyzed using ImageJ software to determine size distribution of
NPs.

Antibody Conjugation to Nanoparticles
Target Selection
Appropriate targets were selected by literature review and with aid from the
LungGENS database (72). Selection criteria required that the targets be cell-surface
markers, present on epithelial cells, and present in pulmonary tissues. Targets
present in fetal lungs were also selected for use in the in utero mouse model.
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Antibodies against selected target antigens, which included podoplanin (PDPN),
surfactant protein C (SFTPC), mucin 1 (MUC1), and intracellular adhesion molecule
(ICAM) were obtained. For each antibody, an appropriate isotype control antibody
was obtained as well. To optimize targeting efficacy, three antigen properties were
analyzed: accessibility, receptor density, and antigen-antibody affinity (73).

Accessibility of the antigens was analyzed by immunofluorescent staining of both
CFBE cells and sections of fetal and adult mouse lung to confirm surface expression
of the target. Cells were fixed with 4% paraformaldehyde (PFA) for 15 minutes at
room temperature and then washed with PBS. Tissues were fixed with 4% PFA prior
to sectioning; frozen sections of thickness 14-16 μm were made. Samples were
blocked with FBS for one hour at room temperature and then incubated with
primary antibody at 1:100 overnight at 4°C. Sections were subsequently washed
with PBS and incubated with the appropriate species of secondary antibody
conjugated to Alexa Fluor 488 fluorophore (Ex = 490nm, Em = 525nm) for 3 hours
at room temperature. Sections were again washed and then counterstained with
DAPI and mounted for analysis by confocal microscopy. Confocal imaging was
performed on a Zeiss Cell Observer SD microscope.

Receptor density and antibody-antigen affinity were determined by antibody
titration curves (53, 74). Cells in 96-well plates were treated in triplicate with 60 μl
of media containing primary antibody in concentrations ranging from 0.1 nM to 100
nM. The corresponding isotype antibody was used as a control for each antibody
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species. The cells were incubated for one hour at 37°C. Cells were washed with
media, treated with 30nM concentration of secondary antibody conjugated to Alexa
Fluor 488 fluorophore in cell culture media, and incubated again for one hour at
37°C. Cells were washed and trypsonized with 0.25% trypsin. Cold fluorescenceactivated cell sorting (FACS) buffer (2% fetal bovine serum in sterile PBS) was
added to each well and cells were collected in individual FACS tubes and kept on ice
for analysis. FACS was performed on an Attune NxT Flow Cytometer by Invitrogen.
Untreated cells were used to determine forward- and side-scatter voltages and
background fluorescence was subtracted from all experimental groups. FlowJo
software was used for FACS analysis. Intensity data generated was used to create a
non-linear one-site specific binding curve using Prism software by GraphPad. The
calculated Bmax value was used to approximate the receptor density. The calculated
Kd was used to approximate the antibody-antigen affinity (75).

Antibody Surface Conjugation
Antibody

conjugation

to

PLA-PEG

NPs

occurred

via

1-ethyl-3-(3-

dimethylaminopropyl)carbodiimide hydrochloride (EDC) mediated carboxyl-amine
crosslinking. Antibodies containing sodium azide or other preservatives were
dialyzed overnight to remove any molecules that could inhibit coupling. The
antibody concentration was adjusted to a working volume of 0.55 mg/ml. The
conjugation reaction occurs in three steps: activation, conjugation, and quenching.
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An aliquot of NPs at 5mg/ml was thawed and sonicated to resuspend the particles.
To activate the NPs, 57 μl of 1 M MES buffer (pH 5.5) was added under vortex. Next,
57 μl of 100 mg/ml sulfo-(N-hydroxysulfosuccinimide) (NHS) was added under
vortex to stabilize the reaction. Finally, 57 μl of EDC was added under vortex to
activate the carboxyl group on the PEG groups. The NPs were vortexed vigorously
for 15 minutes to complete the activation.

For the conjugation phase of the reaction, the NPs were split into two aliquots and
micro-centrifuged at 21,500g for 10 minutes. The antibody was prepared by adding
1 M MES to a final concentration of 50 mM. Once the centrifugation of the NPs was
complete, the supernatant was carefully aspirated and the activated NPs were
resuspended in 50 μl of 50 mM MES in PBS. The activated NPs were then added to
the prepared antibody solution under mild vortex. The NPs were vortexed
vigorously for one hour to complete the conjugation.

To quench the reaction, 6 μl of 1 M Tris buffer (pH 9) was added to the conjugated
NP solution. The NPs were then micro-centrifuged at 21,500g for 10 minutes and
the supernatant was carefully aspirated. The conjugated NPs were resuspended in
PBS and diluted to desired concentration. Aliquots were snap frozen in liquid
nitrogen and stored at -80°C.
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In Vitro Nanoparticle Treatments
Cell Culture
Human bronchial epithelial cells (16HBE O-14)) and cystic fibrosis bronchial
epithelial cells (CFBE41o-) (an immortalized cell line homozygous for the F508
deletion mutation) were cultured at 37°C in growth media (1% L-glutamine, 1%
penicillin-streptomycin, 10% fetal bovine serum in 1x EMEM by Mediatech Inc) on
cell culture places that were pretreated with 0.3 mg/ml rat collagen in sterile 0.1%
acetic acid. Cells were grown to confluence and passaged accordingly.

Cell Seeding
For experimental purposes, cells were seeded onto collagen-treated 48-well or 96well plates. Confluent cells in flask were washed with PBS, treated with TrypLE
Express trypsin, and allowed to incubate for 10 minutes at 37°C. Once detached,
cells were centrifuged and resuspended in fresh media. To count cells, 1:1 aliquot of
cells to dye was used. Equal concentrations of cell suspension were then seeded into
each well. Cells were allowed to adhere and grow for 48 hours before experimental
use.

Conjugated Nanoparticle Treatment
CFBE cells were seeded in 48-well plates. Each batch of antibody-conjugated
nanoparticles was tested at three concentrations: 25 μg/ml, 50 μg/ml, and 100
μg/ml, in 500 μl total volume of cell culture media. Isotype-conjugated nanoparticles
were used as matched controls for each experimental antibody. Cells were
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incubated with the conjugated NPs for 2 hours at 37°C. The cells were subsequently
washed six times with warm FACS buffer before being trypsonized with 0.25%
trypsin. Cold FACS buffer was added to each well and cells were collected in
individual FACS tubes and kept on ice for analysis. Fluorescence-activated cell
sorting (FACS) was performed on an Attune NxT Flow Cytometer by Invitrogen.
Untreated cells were used to determine forward- and side-scatter voltages and
background fluorescence was subtracted from all experimental groups. FlowJo
software was used for FACS analysis.

In Vivo Nanoparticle Treatments
Animal Models
All animal use was in accordance with the guidelines of the Animal Care and Use
Committee of Yale University. Mice used were C57BL/6 mice obtained from Charles
River Laboratories as well as 654-EGFP mice that are genetically modified to contain
a β-globin/GFP fusion gene, consisting of an intron of β-globin within a nonexpressed GFP protein gene.

In Utero Nanoparticle Delivery
To determine the gestational age at which mouse fetuses begin to breathe and
swallow amniotic fluid, mice were crossed and time dated to obtain pregnant
females at 15 to 18 days post-conception. At the desired gestational ages, both intraamniotic and intra-venous injections were performed with dye-loaded PLGA NPs.
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For each procedure, the pregnant female mice were anesthesized with inhaled
isofluorane (3% vol/vol for induction and 2% vol/vol for maintenance). Before
incision, 10 ml of meloxicam was delivered subcutaneously for analgesia. A midline
laparotomy incision was made and the gravid uterus was exposed.

Fetal Biodistribution of PLGA Nanoparticles
For the biodistribution studies, lyophilized PLGA NPs were resuspended in PBS to a
final concentration of 9 mg/ml. The NPs were vortexed and sonicated to achieve
complete resuspension. Intra-vascular injections were performed at E15.5 and
E16.5 (FIGURE 1A). The injections were performed by Dr. David Stitelman, Dr.
James Farrelly, or Dr. Samantha Ahle, using hand-drawn glass micropipettes with tip
diameters of 60 μm. A volume of 15 μl of dye-loaded PLGA NPs was drawn up and
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injected intra-vascularly under a microscope via the vitelline vein of each fetus using
a pneumatic microinjector. Intra-amniotic injections were performed at E15.5,
E16.5, E17.5, and E18.5 (FIGURE 1B). The injections were performed by myself and
Adele Ricciardi using hand-drawn glass micropipettes. A volume of 20 μl of dyeloaded PLGA NPs was drawn up and injected directly into the amniotic cavity of
each fetus.

Pregnant mice were sacrificed 3 hours post NP injection and the fetuses were
delivered by cesarean section. Confirmation of successful injection was done by ex
vivo fetal fluorescence stereomicroscope imaging on a Leica M80 stereomicroscope
(FIGURE 1C). Fetuses were then fixed en bloc in 4% PFA for 24 hours and
subsequently dehydrated in 20% sucrose. Specimens were then embedded in
Optimal Cutting Temperature (OCT) compound and sections were counterstained
with DAPI and mounted for analysis by confocal microscopy. Confocal imaging was
performed on a Zeiss Cell Observer SD microscope.

Fetal Biodistribution Analysis
Fetuses and maternal organs (lung and liver) were fixed for 24 hours in 4% PFA and
then transferred to 20% sucrose for dehydration. The fixed tissues were then
embedded in OCT compound and frozen. Frozen sections were counterstained with
DAPI nuclear dye and mounted on glass slides for confocal imaging analysis.
Confocal imaging was performed on a Zeiss Cell Observer SD microscope.
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Additionally, fetal biodistribution imaging was performed by Adele Ricciardi to look
at whole-fetus and organ-specific fluorescent uptake. For these studies, PLGA NPs
were loaded with 1,1-dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine (DiD) dye
(Ex = 644 nm, Em = 665 nm) for compatibility with the imaging system.
Fluorescence and x-ray imaging of whole fetuses as well as individual fetal organs
was performed on a Carestream In-Vivo MS FX PRO system from Bruker.
Statement of Contribution
The author was responsible for execution of all cell culture experiments,
nanoparticle fabrication and conjugation, intra-amniotic nanoparticle injections,
collection and analysis of all injected fetuses including sectioning, staining, and
microscopy. Intra-venous injections were performed by Dr. David Stitelman and Dr.
James Farrelly. Whole fetus fluorescent xray imaging was performed by Adele
Ricciardi. All remaining data presented herein was generated by the author with
generous support by members of the Stitelman, Saltzman, and Egan laboratories.
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RESULTS

Nanoparticle Synthesis and Characterization
Reproducible Nanoparticle Fabrication
Nanoparticles were fabricated
with two different polymers as
well as two different methods
of synthesis for each polymer
type. Preliminary experiments
were performed to develop
size

curves

consistency

to
in

size

ensure
and

distribution of NPs, regardless
of fabrication method. The size
curve shown in FIGURE 2 was
created for fluorescent dyeencapsulated PLA-PEG NPs synthesized using the NanoAssemblr. By altering the
starting concentration of the polymer, the diameter of the nanoparticles can be
consistently altered. For PLA-PEG NPs, a starting concentration of 30 mg/ml
resulted in 150nm particles. However, for PLGA NPs, a starting concentration of
20mg/ml resulted in 150nm particles (graph not shown). NP size was kept
consistent to eliminate size as a confounder in the biodistribution experiments. As
demonstrated by the polydispersion index (PDI) (FIGURE 2), the size distribution of
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NPs remained consistent for lower concentrations of polymer, but as the
concentration and size increased, there was greater variability in size distribution
(PDI > 0.2). NPs were further characterized by SEM (FIGURE 2), which confirmed
consistent ability to create spherical NPs of desired size and distribution.

Nanoparticle Distribution
Successful Injection of NPs by Intra-amniotic and Intravenous Routes
Fluorescent dye-encapsulated NPs were delivered to developing mouse fetuses
through intra-amniotic (IA) injection at gestational ages E15-E18 and through
intravenous (IV) injection at gestational ages E15-E16. At gestational ages above
E16, the involution of the vitelline vein through which the IV injections are delivered
inhibits consistent and effective injection of NPs. Successful injections of fluorescent
NPs were confirmed by stereomicroscopy images of the fetuses 3 hours after
injection of fluorescent NPs (FIGURE 3). For IA injections, images were taken with
amniotic sac intact to show fluorescence within the amniotic fluid. For IV injections,
images were taken of the fetus without amniotic sac to demonstrate internal
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fluorescence.

Mouse Fetuses Breathe and Swallow Amniotic Fluid at E16
Developing fetuses begin to breathe and swallow amniotic fluid during gestation to
allow maturation and growth of the respiratory and alimentary tracts. Temporal
and spatial targeting of nanoparticles is therefore possible to these organ systems
once the fetus has initiated these actions. Intra-amniotic injection of fluorescent NPs
at days E15-E18 of gestation and subsequent histological analysis demonstrated
that at gestational age E16, NPs are evident throughout the developing lungs as well
as the gut, indicating that the fetuses are breathing and swallowing amniotic fluid
(FIGURE 4).

Differential Organ-Specific Uptake Based on Delivery Route
Nanoparticle administration by either vascular or amniotic fluid routes resulted in
different patterns of accumulation within the organs of the fetuses. Whole fetus
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fluorescent x-ray imaging was performed (FIGURE 5). For IV injected fetuses, the
imaging demonstrates a bright focal accumulation in the abdomen of the fetus that
correlates to the area of the liver. In contrast, for IA injected fetuses, fluorescent
signal appears to be more widespread and correlating more closely with the
entirety of the digestive tract.

Indeed, when examining organ-specific uptake of injected fetuses, the patterns seen
on whole-fetus imaging correspond with the accumulation in each tissue (FIGURE
5). In the IV injected fetuses, the liver demonstrates the highest uptake of NPs, likely
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due to its role in detoxification of the circulating blood. The lungs, which represent
another extensive capillary bed in which NPs would accumulate, also show
moderate uptake of fluorescence. In the IA injected fetuses, as confirmed by
histology, there is no uptake in those fetuses injected at E15 days. However, starting
at E16 and continuing through E18, significant accumulation is noted in the lungs
and guts of the fetuses.

Nanoparticles Remain Within Fetal Circulation
As a safety measure, the livers of the mothers were examined as well. Nanoparticles
injected into fetal circulation via IV injection are not expected to cross the placental
barrier between maternal and fetal circulations. Should NPs enter into maternal
circulation,

they

would

be

expected to undergo first-pass
hepatic uptake and therefore
be

noted

maternal

on

analysis

of

liver.

FIGURE

6

demonstrates that at E15 and
E16 days gestation, IV injection
does not result in detectable
NP

accumulation

maternal mouse.

in

the
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Antibody-Conjugated Nanoparticle Delivery2

Immunohistochemistry Demonstrates Antigen Accessibility
Immunofluorescent staining of CFBE cells (FIGURE 7), sections of fetal mouse lungs
(FIGURE 8), and sections of adult mouse lungs (FIGURE 9) allows visualization of
antigen location within the tissues of interest. The established delivery method of
nanoparticles via the amniotic fluid in a fetal model and intranasally in an adult
model necessitates apical surface localization of the targets, such that antibodyconjugated NPs will be allowed to come into contact with the correct antigen. CFBE
cell staining with anti-PDPN and anti-MUC1 antibodies demonstrates cell membrane
expression. Staining with anti-SFTPC antibody demonstrates robust staining
throughout the cell membrane and cytoplasm (FIGURE 7).
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In sections of E16 fetal mouse lung (FIGURE 8), staining with anti-PDPN, anti-MUC1,
and anti-SFTPC antibodies all demonstrate localization of the target to the luminal
epithelial cells of the lungs, distributed throughout the large and small airways.
Notably there is no staining of the endothelial cells within the vasculature or the
lung parenchyma.

In adult mouse tissues (FIGURE 9), PDPN does not demonstrate epithelial surface
staining in larger airways, though there is diffuse staining within the distal alveoli.
MUC1 retains cell surface staining of epithelial cells throughout large and small
airways. SFTPC demonstrates diffuse staining throughout the distal airways.
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Antibody Binding Curve Approximates Receptor Density and Affinity
Antibody titration curves for candidate surface markers were created with CFBE
cells to determine receptor density and antibody affinity properties. MUC1
fluorescent intensity increased in a dose-dependent manner, while increasing
concentrations of anti-PDPN and anti-SFTPC antibodies did not modulate the
fluorescent signal (FIGURE 10A). At 30nM, a representative intermediate
concentration, comparison of antibody binding compared to isotype is shown in
FIGURE 10B, demonstrating right-shifts of curves created by MUC1, ICAM, and
CD227 antibodies. When fit to a specific binding curve, the Kd and Bmax values can
be calculated for MUC1, CD227, and ICAM (FIGURE 10C). These values are
representative of the antigen-antibody affinity and the receptor density,
respectively.

MUC1 had the greatest Bmax (9191) indicating highest receptor
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density of MUC1 protein on CFBE cells. ICAM had lowest Kd (0.014), correlating
with strongest antibody-antigen affinity.

Conjugation-Dependent Uptake of Nanoparticles
After treatment with antibody-conjugated nanoparticles, CFBE cells demonstrated
conjugation-dependent increased uptake of NPs when conjugated with anti-MUC1
and anti-ICAM antibodies (FIGURE 11). When noting fold-increase of targeting NPs
compared to isotype-conjugated NPs at three different treatment doses, those NPs
specific to MUC1 receptors and ICAM receptors were consistently taken up at higher
concentrations by CFBE cells. ICAM had the greater response, with 4-fold increase
over isotype at 50 μg dosing. MUC1 had consistent 2-fold increase over isotype at all
concentrations.
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DISCUSSION

Congenital abnormalities and genetic disorders afflict millions around the world and
the paucity of effective therapies or cures lead to devastating outcomes (1, 2, 4). In
the United States cystic fibrosis (CF) is the second most common lethal inherited
disorder of childhood, with a prevalence of 1/3700 births (7, 8). The most common
mutation in CF is a three base-pair deletion (delF508) resulting in lack of cell
surface expression of the cystic fibrosis transmembrane conductance regulator
(CFTR) channel (7). Though it is one of the most rigorously characterized genetic
diseases, treatment for CF focuses on symptom management. Gene therapy remains
elusive due to challenges with efficient in vivo delivery in the postnatal host (76).
The burden of genetic diseases such as CF represents an unmet need with lifelong
morbidity and premature mortality resulting from a process that could be amenable
to cure by gene therapy. In utero delivery of targeting nanoparticles, therefore,
presents an opportunity to optimize the efficacy of therapeutic intervention in CF
and other genetic disorders.

Fetal diagnosis is now possible at much earlier gestational ages (9, 10, 12, 13) and
there are several therapeutic advantages to fetal therapy (65). In utero intervention
takes advantage of the fetus’ immunotolerant status as well as small relative size.
Importantly, the developing fetus is composed of proportionally greater numbers of
stem cells, which have been shown to be more susceptible to editing during
development due to their massive proliferation and migration (66-70). Access to
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stem cells has implications for permanent and exponential impact of gene editing, as
each progeny cell would contain the corrected genetic sequence. Unfortunately,
these progenitor cells may no longer be accessed after birth. Prior work by our
group has shown increased efficiency of gene editing in hematopoietic stem cells
compared to somatic cells (35). Similarly, it has been shown that stem cells of the
brain, skin, muscle, and liver are more susceptible to gene editing in utero (65, 69,
70, 77-79).

Intervening during development has the potential for increased and prolonged
overall impact by mitigating disease phenotypes before birth. Nanoparticles have
been shown to be safe and effective vessels for delivery of drugs or other small
molecules (18-22). Active targeting of the nanoparticles increases the specificity and
uptake in the tissues and cells of interest, which has been successfully achieved by
conjugation of specific antibodies (53-55). Taken together, the work herein aims to
explore the potential of targeting nanoparticles, both to add to the growing body of
targeting literature and also to explore the novel application of nanoparticles in a
fetal model.

Prior studies by our group have shown that nanoparticle-based gene editing therapy
can result in mutation correction in a model of cystic fibrosis (58). However, by
intranasal administration in adult mice, correction within the cells of the lungs was
only 1%, which is not sufficient to improve disease phenotype. Studies have
indicated that a 5-10% correction of the CFTR channels is required to achieve
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phenotypically significant levels of ion transport (80). For this reason, we chose to
repeat and expand upon the methods and models used in these studies. We used a
well characterized cystic fibrosis bronchial epithelial cell line (81, 82) as well as
analyzing nasal epithelium of adult mice. We sought to improve delivery of
therapeutic agents with modified nanoparticles to improve the efficiency in editing.

Fetal therapy has been previously explored, particularly in the form of vector-based
gene therapy (65, 69, 70, 77-79), but there is limited research pertaining to in utero
application of nanoparticles. We therefore set out to first determine the
biodistribution of nanoparticles in a fetal mouse model. While physiologic
movements such as swallowing and breathing have been well characterized in the
human fetus (43, 83), we here used a fetal mouse model to better characterize these
actions in mice. The comparison of organ system development between mice and
humans has also been widely studied, allowing for translation of our findings to
clinically relevant time points (84). Examination of fetal organs after intra-amniotic
injection of fluorescent nanoparticles demonstrated that at gestational day 15, there
are no particles within the respiratory or gastrointestinal tracts of the fetal mice.
However, starting at E16 days gestation and increasing in intensity through E18,
significant nanoparticle accumulation is noted throughout the lungs and the
intestines. The pattern of nanoparticle distribution is consistent with literature that
has demonstrated fetal breathing movements and delivery of viral vectors to fetal
lungs and gut at the same gestational age (79, 85, 86). This is a significant finding in
the scope of the overall hypothesis, as appropriate temporal timing is paramount to
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optimize targeting. By intra-amniotic injection, therapies aimed at ameliorating
respiratory or gastrointestinal diseases can be readily delivered to the organs of
interest. Further modifying the nanoparticles will then serve to improve upon the
temporal targeting demonstrated here.

Similarly, intravenous biodistribution of nanoparticles in the fetus was examined. As
with amniocentesis, blood transfusions through the umbilical vein of the human
fetus have been safely performed for many years (14) and provide a viable method
of in utero delivery of nanoparticles. Following intravenous injection of fluorescent
nanoparticles there is high accumulation in the liver of E15 and E16 fetuses. This
finding is supported in other studies that have long shown that there is intense and
rapid hepatic uptake of intravenously injected vessels (87, 88). At E15, there also
appears to be nanoparticle accumulation in the heart, lungs, gut, and kidneys,
whereas injections a day later demonstrate a distribution more limited to lungs and
gut. This biodistribution information is essential in developing targeted therapies, as
any renal or cardiac disorders should be treated before E16 for maximal effect.

Of note, the safety of the proposed model has been proven. In unpublished data
from our group, there is no difference in overall survival of fetal mice that receive in
utero injections compared to fetuses that are not injected. Furthermore, the treated
fetuses that are born have similar life expectancies as well as weights compared to
their untreated counterparts. Additionally, we showed in this study that the
pregnant dams do not get a significant dose of nanoparticles. Any fluorescent

35
particles escaping the fetal circulation into maternal blood would have been taken
up by the maternal liver by first-pass clearance. We did not appreciate any particles
within the maternal livers that were examined. Finally, the dose of particles we
deliver to the fetuses is substantially lower than the systemic doses that must be
delivered to adult mice. In studies with adult mice, 5-7mg of nanoparticles are
required (36, 58), while fetal injections require over 20 times less. If similar effects
can be achieved with smaller doses, the fetal model is both cheaper and safer in
practice.

Taken together, both route of administration and timing of injection contribute to
initial passive targeting of nanoparticles in utero. Specific organs can be
differentially targeted by either amniotic or venous injection. Similarly, the
developmental stage of gestation can further dictate the differential accumulation of
particles based on the breathing and swallowing patterns of the fetus. Importantly,
stem cell migration and expansion patterns also change over development and
could alter accessibility to those progenitor cells (66, 69, 70, 79). Harnessing the
anatomical and temporal biodistribution pattern of nanoparticles can appropriately
target the affected organs of many congenital disorders.

To further increase the efficacy of targeting nanoparticles, surface modifications can
be made, including conjugation of cell-specific antibodies. Based on our
biodistribution studies, we can reliably access tissues of interests. If we can increase
the contact time and therefore uptake of the nanoparticles into those tissues, the
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specificity of delivered therapeutics can be increased. Subsequently, if the particles
are more efficient, we can reduce the systemic dose delivered and decrease the
potential for toxicity. To maximize targeting potential it is important to optimize
accessibility of the receptor, density of the receptor, and antibody-antigen affinity
(53, 59, 74). Therefore, to improve upon the CF phenotype in the lung, the antigens
must localize to the apical surface of epithelial cells where they would come in
contact with inhaled nanoparticles. Visualization of the targets was achieved by
immunohistochemistry, which showed diffuse surface distributions of the receptors
on both the adult human CFBE cells lines as well as the fetal lung sections we
examined. When comparing staining patterns between the fetal and adult
respiratory epithelium, it appears as though mucin 1 (MUC1) retains diffuse
expression throughout the large and small airways. However, podoplanin (PDPN)
and surfactant protein C (SFTPC), while staining throughout the airways in the fetal
lungs, exhibit different expression patterns in the adult lungs. Larger secretory
airways no longer express PDPN and SFTPC, suggesting these markers may not be
accessible for targeting in the adult model.

However, accessibility of the antigen is not sufficient for targeting purposes. We
therefore created antibody binding curves based on dose-dependent binding of
antibodies to CFBE cells. Of our initial targets, binding results from antibodies
against MUC1, CD227 (a different epitope on the mucin 1 receptor), and
intracellular adhesion molecule 1 (ICAM) fit to one-site specific binding curves.
From the binding curves we can approximate the receptor density (Bmax) and the
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antigen-antibody binding affinity (Kd) (75). To our knowledge, this is the first time
these markers have been assessed in this manner on epithelial cells. These values,
therefore, represent a relative scale that is applicable only to this model. The Bmax
of MUC1 approached 10,000, representing the highest receptor density. However,
the Kd value of ICAM was strongest at 0.014, indicating the highest binding affinity.
The ideal target optimizes both values to achieve the best nanoparticle binding
results.

We then proceeded with antibody conjugation reactions of fluorescent dye-loaded
nanoparticles and in vitro treatment of CFBE cells at different concentrations. Not
surprisingly, good receptor density and antibody affinity by binding curve
translated

into

conjugation-dependent

uptake

of

antibody-conjugated

nanoparticles. When compared to an isotype control, both MUC1 and ICAM
demonstrated increased nanoparticle uptake, with a four-fold increase in uptake for
ICAM-conjugated nanoparticles. Interestingly, the highest treatment dose of
nanoparticles did not translate into increased uptake. This is likely due to diffusionlimited movement of the nanoparticles. The nanoparticles are dense and settle on
the surface of the cell monolayer and are therefore limited by the rate at which the
particles can diffuse to contact the cell surface. Other studies have shown similar
results of conjugation-dependent nanoparticle uptake. These studies, using different
cells and markers, have shown up to 80-fold increase of uptake (53-55, 89, 90).
These results are encouraging and indicate that we can continue to improve upon
our targeting with our current model.
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Of the targets we tested, MUC1 and ICAM demonstrated the greatest increase in
uptake. MUC1 is part of the mucin family of genes found on epithelial cells and is
expressed on apical surface of epithelial cells that line the mucosal surfaces of many
different tissues, including the lung (91-93). In fact, MUC1 is upregulated in many
epithelial cancers and is therefore a common cancer target. Successful targeting of
this protein has been shown in other studies (94, 95), further validating our results.
Interestingly, MUC1 is also found in stomach and pancreas, which could have
additional implications for targeting cystic fibrosis, as these organs are also affected.
Additionally, MUC1 is expressed as early in gestation as E12 in fetal mouse lungs
(93), as well as in most airway epithelial cells in the adult lung, indicating that this
could be a powerful target for both fetal and post-natal editing.

ICAM-conjugated nanoparticles were also found to result in consistently increased
uptake in CFBE cells. Though often thought of as an endothelial cell marker, ICAM
has also been found to be involved in neutrophil recruitment via respiratory
epithelium (96). Furthermore, in inflammatory states of pulmonary diseases such as
CF, ICAM expression is upregulated on the surface of respiratory epithelium, making
this an even more significant receptor for therapeutic targeting (97). Additionally,
because ICAM is also found on the surface of endothelial cells, nanoparticles that
target this receptor could be successfully administered from both the intra-amniotic
and intravenous routes.
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Interestingly, we noted an unexpected difference between uptake of nanoparticles
conjugated with anti-MUC1 antibodies compared to anti-CD227 antibodies. Both
antibodies are specific to the MUC1 protein, though the antibodies bind two
different epitopes. On analysis of the antibody binding curves, CD227 had a similar
Bmax compared to ICAM, and we expected these nanoparticles to perform at least as
well as MUC1 and ICAM. However, in practice, the CD227-specific nanoparticles
demonstrated only a slight increased uptake compared to control nanoparticles at
the lowest dose. One possible explanation is the location of the CD227 epitope.
When conjugating antibodies to significantly larger nanoparticles, steric hindrance
may prohibit binding of antibodies to their targets. Though the antibody
independently was able to bind and produce a binding curve, this alone cannot
guarantee that the conjugated nanoparticle will be equally successful.

When creating antibody binding curves for antibodies that appeared to be on the
surface of CFBE cells by staining, both PDPN and SFTPC failed to produce dosedependent specific binding curves. Both of these receptors had been selected after a
thorough literature search and validation in the LungGENS database, a single-cell
gene expression database specific for fetal mouse lungs (72). We were further
bolstered by the high apparent expression of both targets throughout the airways of
fetal mice as determined by immunohistochemistry. There are several possible
explanations for this unexpected outcome. First, it is possible that either the
receptor density or the quality of the antibody itself were inadequate to be a
successful target. Second, although fetal mouse lungs exhibited strong expression of
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PDPN, when comparing to adult mouse lungs, there is a different pattern of
expression and we may no longer be targeting the correct cells. Differential
expression of PDPN has been demonstrated between fetal and adult lungs and
therefore age may affect the available receptors (98). Finally, even though fetal
mouse lungs appeared to have a strong signal, the antibody binding curve is created
using an immortalized adult human bronchial epithelial cell line, presenting a
mismatch in both development stage and species. Therefore, even though PDPN was
not a successful target in an adult cell line, it may be reasonable to repeat the study
in vivo in fetal mice.

The inability to effectively translate our results between species and between ages
was one of the limitations of this study. While in vitro work provides a convenient
and consistent model in which to quickly test different antibody targets, there is no
guarantee that the results will translate in vivo. There is certainly less predictability
in an animal model and fewer factors that we can control. One method that has been
presented in the literature that could address this limitation is quantitative
microscopy (53). Using sections of fetal mouse lung and identical staining and
imaging techniques, it may be possible to create dose-dependent curves and thereby
estimate the receptor density and antibody-antigen affinity in situ. Similarly,
translation between species, in this case human and mouse, is not always possible
and therefore the identification and characterization of targets should be performed
in the tissues of interest for targeting. Identification of a mouse epithelial cell line
will therefore be crucial for more efficient target selection.
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There are several future studies to be performed to expand upon the results
presented in this study. While we were able to demonstrate increased uptake of
nanoparticles into cells, the therapeutic efficacy of the particles is dependent on the
ability to deliver the payload (99). In the context of our study, the next step is to
demonstrate that preferential collection of particles in our target cells indeed leads
to higher rates of gene editing. Subsequently, we will also be performing in vivo
conjugation studies. With the use of quantitative microscopy and FACS to analyze
differential uptake, we hope to show improved efficacy of targeting nanoparticles
into the lungs of a fetal mouse model. Finally, our group has ongoing studies further
modifying the molecular characteristics of particles, including the size of the
particles as well as the polymer type. It has been shown that size and composition of
particles can also affect the biodistribution and therefore can impact targeting (42,
99-101). Thus, while our data demonstrates increased uptake efficiency and
specificity with targeting nanoparticles, further work is warranted to continue
optimizing this technology.

In summary, we present here new insights into targeting nanoparticles to specific
cell and tissue types, both in vitro and in vivo. We have demonstrated differential
biodistribution after in utero injection of nanoparticles that can be reproducibly
altered to target specific organs. Furthermore, we have demonstrated that we can
increase uptake of nanoparticles in a conjugation-dependent manner to further help
to increase our targeting efficiency. This work provides the foundation for further
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study into targeting in vivo, both in adult and fetal mouse models, so that we can
obtain greater therapeutic efficacy via nanoparticle delivery. Indeed, imminent work
from our group will seek to demonstrate greater gene editing efficiency in a cystic
fibrosis model in the hopes of achieving phenotypic improvement. Targeting
technology can be applied to a wide range of therapies and disorders, and in utero
application of this technology increases the therapeutic potential of nanoparticles.
Future work will influence our understanding of disease and the outcomes of many
congenital disorders.
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